Amgen promotes Robert Bradway to president
pharmafile | April 28, 2010 | Appointment | Manufacturing and Production, Sales and Marketing | Amgen, appointment, manufacturing and production, sales and marketing
Robert Bradway has been appointed president and chief operating officer at US biotech Amgen.
Bradway, currently executive VP and chief financial officer, will assume his new role on 11 May, when he will take responsibility for Amgen’s global commercial operations.
His remit will also include overseeing strategy and corporate development, information technology, manufacturing operations and global government affairs and compliance.
Bradway first joined Amgen in 2006 as VP, operations strategy, prior to which he was a managing director at Morgan Stanley in London where he had responsibility for the firm’s banking department and corporate finance activities in Europe.
He joined Morgan Stanley in New York as a health care industry investment banker in 1985 and moved to London in 1990 where he served as head of the firm’s international health care investment banking activities until assuming broader corporate finance management responsibilities.
Meanwhile, Amgen’s executive vice president of global commercial operations George Morrow will retire 31 January 2011.
Morrow became executive vice president of worldwide sales and marketing for Amgen in January 2001, and executive vice president, global commercial operations in April 2003.
Prior to Amgen, he was president and chief executive of Glaxo Wellcome Inc, the US subsidiary of what is now GlaxoSmithKline.
Finally, from 11 May Michael Kelly, Amgen’s vice president of finance and chief accounting officer, will serve as acting chief financial officer. He joined Amgen in 2003 and has served as chief accounting officer since 2005.
Related Content
Rotzinger launches modular filling and capping platform for over-the-counter products
Rotzinger PharmaPack has launched a new filling and capping platform called VarioFill, designed to handle …
David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer
Amgen has announced that the US Food and Drug Administration (FDA) has approved Imdelltra (tarlatamab-dlle) …
